心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 ESH意见书：高血压和射血分数保留的心力衰竭

2021-05-30 欧洲高血压学会 J Hypertens. 2021 Aug 1;39(8):1522-1545

高血压心力衰竭

2021年5月，欧洲高血压学会（ESH）发布了高血压合并射血分数保留的心力衰竭的立场文件，对各类药物临床研究进行了梳理，并提出了临床管理策略。涉及的主要药物包括血管紧张素转换酶抑制剂（ACEI）、血管

中文标题：

2021 ESH意见书：高血压和射血分数保留的心力衰竭

英文标题：

Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

发布机构：

欧洲高血压学会

发布日期：

2021-05-30

简要介绍：

2021年5月，欧洲高血压学会（ESH）发布了高血压合并射血分数保留的心力衰竭的立场文件，对各类药物临床研究进行了梳理，并提出了临床管理策略。涉及的主要药物包括血管紧张素转换酶抑制剂（ACEI）、血管紧张素受体阻断剂（ARB）、血管紧张素受体脑啡肽酶抑制剂（ARNI）、钙离子拮抗剂（CCB）、盐皮质激素受体拮抗剂（MRA）、钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂等。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ESH意见书：高血压和射血分数保留的心力衰竭.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9e28c1c0021a2266, title=2021 ESH意见书：高血压和射血分数保留的心力衰竭, enTitle=Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension, guiderFrom=J Hypertens. 2021 Aug 1;39(8):1522-1545, authorId=0, author=, summary=2021年5月，欧洲高血压学会（ESH）发布了高血压合并射血分数保留的心力衰竭的立场文件，对各类药物临床研究进行了梳理，并提出了临床管理策略。涉及的主要药物包括血管紧张素转换酶抑制剂（ACEI）、血管, cover=https://img.medsci.cn/2021731/1627739568001_2020535.jpg, journalId=0, articlesId=null, associationId=633, associationName=欧洲高血压学会, associationIntro=null, copyright=0, guiderPublishedTime=Sun May 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年5月，欧洲高血压学会（ESH）发布了高血压合并射血分数保留的心力衰竭的立场文件，对各类药物临床研究进行了梳理，并提出了临床管理策略。涉及的主要药物包括血管紧张素转换酶抑制剂（ACEI）、血管紧张素受体阻断剂（ARB）、血管紧张素受体脑啡肽酶抑制剂（ARNI）、钙离子拮抗剂（CCB）、盐皮质激素受体拮抗剂（MRA）、钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂等。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=274, tagName=高血压), TagDto(tagId=335, tagName=心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=335, guiderKeyword=心力衰竭, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2865, appHits=136, showAppHits=0, pcHits=403, showPcHits=2727, likes=0, shares=10, comments=8, approvalStatus=1, publishedTime=Sat Jul 31 22:51:53 CST 2021, publishedTimeString=2021-05-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Sat Jul 31 21:52:53 CST 2021, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 00:12:47 CST 2024, courseDetails=[], otherVersionGuiders=[OtherVersionToolGuiderDto(projectId=1, id=d2d791c00265197c, title=欧洲高血压学会射血分数保留的心力衰竭伴高血压患者管理指南解读, enTitle=, guiderPublishedTime=Mon Aug 15 00:00:00 CST 2022, createdTime=Wed Sep 07 10:39:55 CST 2022)], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ESH意见书：高血压和射血分数保留的心力衰竭.pdf)])
2021 ESH意见书：高血压和射血分数保留的心力衰竭.pdf
下载请点击：
其他版本
欧洲高血压学会射血分数保留的心力衰竭伴高血压患者管理指南解读
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1225012, encodeId=f67112250125d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3b95491711, createdName=ms5000001142840275, createdTime=Tue Jun 07 17:27:24 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070284, encodeId=c17810e0284f6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4405459521, createdName=ms1000001336847167, createdTime=Sun Nov 14 23:18:44 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057146, encodeId=e49f105e14689, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:25:37 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007346, encodeId=67b5100e346d9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:29 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006512, encodeId=d5a7100651285, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6de91548468, createdName=qingbao2004, createdTime=Mon Aug 09 23:29:10 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2022-06-07 ms5000001142840275

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1225012, encodeId=f67112250125d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3b95491711, createdName=ms5000001142840275, createdTime=Tue Jun 07 17:27:24 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070284, encodeId=c17810e0284f6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4405459521, createdName=ms1000001336847167, createdTime=Sun Nov 14 23:18:44 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057146, encodeId=e49f105e14689, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:25:37 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007346, encodeId=67b5100e346d9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:29 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006512, encodeId=d5a7100651285, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6de91548468, createdName=qingbao2004, createdTime=Mon Aug 09 23:29:10 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-11-14 ms1000001336847167

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1225012, encodeId=f67112250125d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3b95491711, createdName=ms5000001142840275, createdTime=Tue Jun 07 17:27:24 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070284, encodeId=c17810e0284f6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4405459521, createdName=ms1000001336847167, createdTime=Sun Nov 14 23:18:44 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057146, encodeId=e49f105e14689, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:25:37 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007346, encodeId=67b5100e346d9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:29 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006512, encodeId=d5a7100651285, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6de91548468, createdName=qingbao2004, createdTime=Mon Aug 09 23:29:10 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-10-03 H8888888

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1225012, encodeId=f67112250125d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3b95491711, createdName=ms5000001142840275, createdTime=Tue Jun 07 17:27:24 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070284, encodeId=c17810e0284f6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4405459521, createdName=ms1000001336847167, createdTime=Sun Nov 14 23:18:44 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057146, encodeId=e49f105e14689, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:25:37 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007346, encodeId=67b5100e346d9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:29 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006512, encodeId=d5a7100651285, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6de91548468, createdName=qingbao2004, createdTime=Mon Aug 09 23:29:10 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-12 ms9000000533661856

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1225012, encodeId=f67112250125d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3b95491711, createdName=ms5000001142840275, createdTime=Tue Jun 07 17:27:24 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070284, encodeId=c17810e0284f6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4405459521, createdName=ms1000001336847167, createdTime=Sun Nov 14 23:18:44 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057146, encodeId=e49f105e14689, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:25:37 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007346, encodeId=67b5100e346d9, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:29 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006512, encodeId=d5a7100651285, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6de91548468, createdName=qingbao2004, createdTime=Mon Aug 09 23:29:10 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-09 qingbao2004

    学习了

    0

相关指南

2021 AHA科学声明：体育锻炼作为高血压或胆固醇升高一线治疗的重要组成

美国心脏协会(AHA,American Heart Association) · 2021-06-02

2021 昆士兰临床指南：高血压和妊娠

昆士兰卫生组织(QLD,Queensland Health) · 2021-05-01

中国高血压患者心率管理多学科专家共识（2021年版）

暂未更新 · 2021-04-20

中国高龄老年人血压水平适宜范围指南

中华预防医学会(CPMA,Chinese Preventive Medicine Association) · 2021-03-20

2021 EAPC/ESC共识文件：个体化运动处方在高血压防治中的应用

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-03-24

2021 SIIA共识文件：睡眠障碍、高血压和心血管疾病的诊断和治疗方法

暂未更新 · 2021-02-25

拓展阅读

2010 中华医学会 急性心力衰竭诊断和治疗指南

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2010-01-01

心脏再同步治疗慢性心力衰竭的建议（2009年修订版）

中华医学会心电生理和起搏分会 · 2010-02-25

加拿大心衰诊疗指南（2010更新）：少数民族人口，心脏衰竭和怀孕，疾病管理，和质量改进/保证方案心力衰竭

加拿大心血管学会(CCS,Canadian Cardiovascular Society) · 2010-04-01

2010HFSA 心力衰竭治疗指南

美国心衰学会(HFSA,HEART FAILURE SOCIETY OF AMERICA) · 2010-07-01

2011AHA/ACC 急性心力衰竭综合征：急诊科表现、治疗、处置的现状及预期目的--来自美国心脏病协会科学声明

美国心脏协会(AHA,American Heart Association) · 2011-04-14

2012AHA 科学声明：心力衰竭诊疗进展科学决策

美国心脏协会(AHA,American Heart Association) · 2012-03-05